A dvances in coronary revascularization markedly lowered the acute phase mortality in myocardial infarction (MI). [1] [2] [3] [4] Nevertheless, the number of post-MI heart failure has been increasing significantly, because the presence of unsalvaged myocardium leads to the development and progression of left ventricular (LV) remodeling and failure in the long term. 5, 6 Thus, there remain clear unmet needs to salvage more myocardium in the management of MI to prevent subsequent heart failure.
Reducing myocardial oxygen consumption (MVo 2 ) is well known to decrease the infarct size in MI, because imbalance between myocardial oxygen supply and demand is the fundamental pathophysiology of MI. 7 Therefore, reducing MVo 2 reestablishes the balance in the setting of reduced oxygen supply. The pressurevolume area (PVA), a specific area circumscribed by the end-systolic, end-diastolic PV relation curves, and PV loop represent the total LV mechanical work. Because PVA is tightly coupled with MVo 2 , 8, 9 a treatment that reduces PVA is expected to decrease MVo 2 .
LV assist devices (LVADs) support hemodynamics and unloads the LV by reducing the PVA. In addition, the latest advance in state-of-the-art medical technology has allowed us the development of minimally invasive transvascular LVADs such as Impella (Abiomed Inc, Danvers, MA) and TandemHeart (Cardiac Assist Inc, Pittsburgh, PA), which can be placed percutaneously. Several investigators have demonstrated that the mechanical unloading of LV during acute MI significantly reduced infarct size. [10] [11] [12] Recently, Kapur et al 13 proposed the concept of door to unloading and demonstrated the importance of earlier unloading in reducing infarct size. In those studies, the degree of LV unloading was not precisely quantified or defined. We demonstrated that, in a dog model of ischemia/reperfusion (I/R), total support of LVAD, where the LV no longer ejects, maximally reduced infarct size. In contrast, with partial support, where the LV remains ejecting, the reduction of infarct size was limited.
14 Despite such an establishment of mechanical unloading in reducing infarct size, it remains unclear whether mechanical unloading preserves LV function and prevents subsequent heart failure in the long term.
The purpose of this study was to examine whether the impact of LV mechanical unloading by the total support of LVAD in a dog model of I/R affects infarct size, LV function, and the development of heart failure in the chronic phase. Among transvascular LVADs, we used Impella because it is the least invasive clinically approved device and takes only 10 to 15 minutes to implant 15 ; therefore it can be readily translated into clinical practice.
METHODS
The data that support the findings of this study are available from the corresponding author on reasonable request.
Experiments and animal care were approved by the Committee on Ethics of Animal Experiments, Kyushu University Graduate School of Medical Sciences, and performed strictly in accordance with the Guidelines for Animal Experiments of Kyushu University and national standard, the Eighth Edition of the Guide for the Care and Use of Laboratory Animals published by National Academy Press. Mongrel dogs (n=20; 14.5-18.5 kg) were used in this study. The information about basic animal maintenance (including housing, enrichment, and feeding) is described in Method I in the Data Supplement.
I/R Model
After inducing anesthesia by intravenous injection of pentobarbital sodium (25 mg/kg) and vecuronium bromide (0.2 mg/kg), we started mechanical ventilation to maintain physiological pH and oxygen saturation. Isoflurane 1% to 3% was inhaled continuously to maintain an appropriate level of anesthesia. Body temperature was maintained at 37°C to 38°C. A catheter (5F) was placed in the left femoral vein for administering fluids. The heart was exposed and the pericardium opened via a left lateral thoracotomy at the fifth intercostal space. We then ligated the left anterior descending coronary artery and the major diagonal branches with 3-0 silk sutures.
WHAT IS NEW?
• Although the acute impact of left ventricular (LV) mechanical support in myocardial infarction (MI) on infarct size was known, its effect on long-term LV function remained unknown. Thus, we examined how the mechanical LV support by transvascular LV assist device Impella affects infarct size and LV function 1 month after MI.
• Partial support by Impella (p-Impella) moderately reduces LV mechanical work, whereas total support (t-Impella) markedly reduces LV mechanical work.
• In an ischemia/reperfusion animal model, total support markedly reduced infarct size and preserved LV function to a greater extent than partial support 1 month after MI.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Recent advances in transvascular LV assist devices such as Impella enable us to translate the concept of mechanical unloading into a practical clinical tool for MI. • This study indicated that total hemodynamic support by Impella before reperfusion markedly reduced infarct size and preserved LV function 1 month after MI.
• Because the presence of residual myocardial damage leads to LV remodeling and failure, total support by Impella may have the potential to prevent subsequent heart failure in MI.
We also ligated the left circumflex coronary artery branches that potentially perfuse the left anterior descending coronary artery area to minimize the effect of collateral circulation as described previously. 16 We cut the ligating sutures for reperfusion at 180 minutes after the induction of ischemia.
For hemodynamic monitoring during MI surgery, we measured arterial pressure (AP) in the right femoral artery using a fluid-filled catheter-transducer system (Model DX-200; Nihon Kohden, Tokyo, Japan) and LV pressure (LVP) using a 5F Millar catheter (SPR-450, Millar Instruments, Houston, TX) inserted through the LV free wall. Sixty minutes after reperfusion, we terminated Impella support and closed the chest by suturing muscles, subcutaneous tissues, and skin. Intravenous cefazolin (20 mg/kg IV) was given twice prophylactically, before and 60 minutes after reperfusion. Carprofen (4.4 mg/kg) was also administered subcutaneously 60 minutes after reperfusion for postoperative analgesia.
LV Mechanical Unloading by Impella
We used an Impella CP (Abiomed Inc, Danvers, MA) capable of generating flow up to 3.5 L/min. Because it was not possible to insert the Impella CP catheter via the femoral artery in dogs, we inserted the Impella catheter directly into the left subclavian artery and advanced to an appropriate position in the LV under fluoroscopic guidance (Figure 1 ) just before starting Impella support. We also cut down the pigtail part of the Impella catheter to fit the size of the dog's LV. As shown in Figure 2 , changes in PV loop by Impella support are dramatically different among support levels. In this study, we conducted 2 modes of LV support using Impella: partial (p-Impella) and total (t-Impella) support. p-Impella is partial LV support, in which the LV remains ejecting. In p-Impella, we adjusted the Impella flow to halve the AP pulse pressure. In a preliminary study (Figure in the Data Supplement), we confirmed that the ratio of the pulse pressure during Impella support to the pulse pressure during no support correlates linearly with the ratio of native cardiac output to total cardiac output (sum of LV ejection flow and Impella flow). Therefore, when p-Impella halved the pulse pressure, we assumed that native cardiac output equals Impella support flow. In contrast, t-Impella is a condition where Impella fully supports hemodynamics, and therefore the LV no longer ejects. In this condition, LVP is very low and never reaches AP. Total unloading is defined as an extreme case of t-Impella where PVA is reduced to zero. This is to say that end-systolic volume has to be reduced to V 0 to make LVP zero. In acute MI, where many variables that affect hemodynamics are unstable and actively changing, achieving total unloading is impractical if not impossible in particular manual controlling of Impella. Because PVA independent MVo 2 accounts for nearly 50% of total MVo 2 , 14 the difference of MVo 2 between t-Impella with sufficiently low LV systolic pressure and total unloading may not be substantial in determining infarct size.
Experimental Protocol
The protocols are shown in Method II in the Data Supplement. We randomly allocated 20 dogs into 4 groups: sham (thoracotomy only, no left anterior descending coronary artery occlusion or Impella support; n=5), I/R (180 minutes ischemia followed by 60 minutes reperfusion, no Impella support; n=5), p-Impella (p-Impella from 60 minutes after onset of ischemia to 60 minutes after reperfusion; n=5), t-Impella (t-Impella from 60 minutes after onset of ischemia to 60 minutes after reperfusion; n=5). Four weeks after MI operation, we evaluated LV function, parameters of heart failure, and infarct size in each dog.
Assessment of Post-MI LV Function, Heart
Failure Parameters, and Infarct Size
Echocardiographic Analysis
All dogs were evaluated by echocardiography 1 month after I/R. We placed each conscious dog into a sling frame (DFH1PU and DFC1PU, Bio Research Center Inc, Nagoya, Japan) and performed transthoracic echocardiography using a 2.18 Hz transducer (iU22, Philips, Amsterdam, Netherlands). We estimated LV end-systolic volume, LV end-diastolic volume, and LV ejection fraction using the modified Simpson method.
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N-Terminal Pro-B-Type Natriuretic Peptide
We collected blood samples just before the induction of anesthesia and measured NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels by enzyme-linked immunosorbent assays (ELISA, Cardiopet proBNP; IDEXX Laboratory, Inc, Tokyo, Japan).
Hemodynamic Analysis
Four weeks after I/R, animals were anesthetized by intravenous injection of pentobarbital sodium (25 mg/kg) and vecuronium bromide (0.2 mg/kg) and were artificially ventilated. Sheaths (5F) were placed into the right femoral artery to measure AP and bilateral femoral veins to administer pentobarbital sodium (2.5 mg/kg per h) and saline (1-2 mL/kg per h as needed). A 6F Millar catheter was inserted from the right common carotid artery into the LV to measure LVP. After obtaining heart rate, AP and LVP data in each dog, we then conducted a median sternotomy and opened the pericardium widely. Fluidfilled catheters were placed directly into both atria to record Left ventriculography image during Impella placement. Contrast medium was injected from the left atrium. We inserted the Impella catheter directly into the left subclavian artery and advanced to an appropriate position in the left ventricle via the aortic valve under fluoroscopic guidance.
right and left atrial pressures. We also implanted 2 pairs of sonomicrometry crystals in the endocardium of LV to measure the anterior/posterior (short axis) and base/apex (long axis) dimensions. Assuming a modified ellipsoidal geometry for LV, we calculated LV volume by the following equation: LV volume=(π/6)×(long-axis dimension)×(short-axis dimension). 2 We obtained LV end-systolic elastance as an index of LV systolic function by using the inferior vena cava occlusion method described previously. 18 Briefly, we determined V 0 , the volume axis intercept of end-systolic pressure-volume relationship, and subtracted V 0 from volume axis. LV stroke volume measured by sonomicrometry crystals was calibrated against those measured by ultrasonic flow probe (Model 12PSB 508; Transonic, Ithaca, NY) placed on the ascending aorta. Then, we calculated the slope of end-systolic pressure-volume relationship from PV loops in each subject.
Infarct Size
We euthanized dogs by infusing potassium chloride after the hemodynamic measurements. We then excised the heart, dissected the left atrium, right atrium, and right ventricle, and cut the LV into 4 horizontal slices (1 cm in thickness) from the apex to base. Each LV slice was stained with 1% triphenyltetrazolium chloride at 37°C for 15 minutes to enhance the infarct area as described previously. 16 We photographed all stained slices and quantified the ratio of the sum of infarct area in 4 slices to the sum of whole LV circumferential area in the same 4 slices using computer software (Image J, National Institutes of Health, Bethesda, Maryland).
Data Analysis
We digitized all analog signals at 200 Hz with a dedicated laboratory computer system equipped with 16-bit analog-to-digital converter (PowerLab 16/35, AD Instruments, Dunedin, New Zealand). Hemodynamics during I/R except for baseline data were evaluated by ANCOVA that adjusted for baseline with Fisher's protected least significant difference test. NT-proBNP was evaluated by nonparametric Kruskal-Wallis test. Others were evaluated by 1-way factorial analysis of variance followed by a Tukey-Kramer test for post hoc comparisons. Data were analyzed using statistical software (Ekuseru-Toukei 2013; Social Survey Research Information Co Ltd, Tokyo, Japan). Differences were considered significant at a P value <0.05.
RESULTS
Hemodynamics During I/R
All 20 dogs survived until the end of the experiments. Baseline hemodynamics (before ischemia) did not differ significantly among 4 groups ( Table 1) . Mean AP did not differ among 4 groups during I/R. I/R increased LV end-diastolic pressure (LVEDP) compared with sham. Figure 3 shows the representative LVP and AP obtained from 1 dog each in the I/R, p-Impella, and t-Impella groups. As suggested in the Methods section, LVP approximated AP in systole in I/R and p-Impella dogs but was totally uncoupled from AP in t-Impella dogs. Thus, peak LVP in the t-Impella group was markedly low at 180 minutes after ischemia onset and at 60 minutes after reperfusion compared with other groups (Table 1) . Compared with I/R, p-Impella significantly lowered LVEDP, whereas t-Impella further lowered LVEDP at 180 minutes after ischemia onset (Table 1) .
Echocardiographic Data
Four weeks after I/R, we performed echocardiography in each dog under conscious condition. As shown in Figure 2 . Definition of Impella support levels. Thin and bold pressure-volume (PV) loops indicate baseline and Impella-supported conditions, respectively. The impact of Impella on the PV area (PVA) depends on the balance between decreased preload and increased afterload. In partial support (p-Impella), in which the left ventricle (LV) remains ejecting, total cardiac output increases, thereby increasing arterial pressure (AP). This leads to increase in LV end-systolic volume (ESV) despite marked reduction in LV end-diastolic volume (EDV). Consequently, p-Impella does not reduce PVA as much as it decreases EDV. On the other hand, in total support (t-Impella), the LV no longer ejects because LV pressure never reaches AP. Thus, t-Impella makes PVA extremely small. Total unloading of Impella is defined as an extreme case of LV mechanical unloading in which PVA is reduced to zero. EDPVR indicates end-diastolic pressure-volume relation; ESPVR, end-systolic pressure-volume relationship; V 0 , the volume intercept of ESPVR; and V u , the volume intercept of EDPVR. Figure 4 , LV end-diastolic volume did not change significantly among groups. In contrast, I/R significantly increased LV end-systolic volume compared with sham, whereas t-Impella significantly decreased LV end-systolic volume compared with I/R (sham, 12.0±3.4; I/R, 22.6±7.1; p-Impella, 19.8±5.8; and t-Impella, 13.0±2.0 mL; P=0.0097). Consequently, LV ejection fraction in the t-Impella group was significantly higher than that in the I/R and p-Impella groups (sham, 64.0±2.7; I/R, 46.8±4.0; p-Impella, 50.4±5.8; and t-Impella, 68.6±4.4%; P<0.001), indicating a protective effect of t-Impella on LV systolic function. In addition, no aortic valve regurgitation was observed in either p-Impella or t-Impella groups. Hemodynamics at baseline (before induction of myocardial infarction), 60 min after onset of ischemia (I-60, just before Impella initiation), 180 min after onset of ischemia (I-180), and 60 min after reperfusion (R-60, just before Impella termination). Experimental groups are as described in Methods section. Data are expressed as mean±SD. HR indicates heart rate; I/R, ischemia/ reperfusion; LVEDP, left ventricular end-diastolic pressure; LVP, left ventricular pressure; MAP, mean arterial pressure; p-Impella, partial support; and t-Impella, total support. Hemodynamics, LV Function, and Heart Failure Parameters Table 2 shows the hemodynamics at 4 weeks after I/R. All data were obtained under general anesthesia. Heart rate and mean arterial pressure were not significantly different among 4 groups. p-Impella and t-Impella significantly reduced LVEDP and left atrial pressure compared with I/R indicating an improvement of pulmonary congestion. The maximum time derivative of LV pressure (Max +dP/dt) was not significantly different among 4 groups. The negative peak time derivative of LVP (Min −dP/dt) was lower in t-Impella than in I/R. Figures 5A and 5B represent the PV analysis. I/R significantly decreased LV end-systolic elastance, a load insensitive index of LV contractility, compared with sham (sham, 11.7±1.6 versus I/R, 4.3±0.8 mm Hg/mL; P<0.05). Compared with I/R and p-Impella, the t-Impella group had a significantly higher LV end-systolic elastance (I/R, 4.3±0.8; p-Impella, 7.0±1.6; and t-Impella, 13 .9±5.1 mm Hg/mL; P<0.05 for t-Impella versus p-Impella, P<0.001 for t-Impella versus I/R).
Serum NT-proBNP levels as an index of severity of heart failure were significantly higher in I/R than in sham (I/R, 4081±1123 versus sham, 936±195 pmol/L; P<0.05; Figure 5C ). Both p-Impella and t-Impella significantly decreased NT-proBNP compared with I/R (p-Impella, 2122±1080 and t-Impella, 1773±390 pmol/L; P<0.05). Figure 6A shows representative digital images of the infarct area in the I/R, p-Impella, and t-Impella groups. Each image was obtained from the second slice from the apex of the excised heart. p-Impella significantly reduced infarct size compared with I/R, whereas t-Impella strikingly reduced the infarct size by 87% relative to I/R (I/R, 16.3±2.6; p-Impella, 8.5±4.3; and t-Impella, 2.1±1.6%; P<0.001; Figure 6B ).
Infarct Size
Figure 4. Echocardiographic measurements at 4 wk after ischemia/reperfusion (I/R).
LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), and LV ejection fraction (LVEF) were measured on 2-dimensional echocardiograms using the modified Simpson method. Experimental groups are as described in the Methods section. LVEF was significantly higher in the t-Impella group than in the I/R and partial support (p-Impella) groups. Data are expressed as mean±SD. *P<0.05 vs sham; †P<0.001 vs sham; ‡P<0.05 vs I/R; §P<0.001 vs I/R; ∥P<0.05 vs p-Impella. Heart rate (HR), mean arterial pressure (MAP), and left ventricular pressure (LVP) data were obtained before thoracotomy. Experimental groups are as described in the Methods section. Data are expressed as mean±SD. I/R indicates ischemia/reperfusion; LAP, left atrial pressure; LVEDP, left ventricular enddiastolic pressure; Max +dP/dt, the positive max derivation of left ventricular pressure; Min −dP/dt, the negative peak derivation of left ventricular pressure; p-Impella, partial support; RAP, right atrial pressure; and t-Impella, total support. 
DISCUSSION
This study was designed to prove the beneficial impact of LV mechanical unloading using Impella with different degrees of support in the acute phase of MI on LV function and parameters of heart failure. We demonstrated that Impella was capable of achieving total circulatory support during I/R in a dog heart. Four weeks after I/R, t-Impella strikingly reduced infarct size by >80% preserved LV function and prevented subsequent heart failure.
Effects of LV Mechanical Unloading by Impella During I/R on Hemodynamics
Hemodynamic stability during the acute phase of MI is vital because acute heart failure is often fatal, and hemodynamic instability often impedes successful early coronary reperfusion. Several investigators have reported the hemodynamic improvement by Impella in patients undergoing high-risk percutaneous coronary intervention [19] [20] [21] or in those with cardiogenic shock. 22 In the PROTECT II ) was significantly greater in the t-Impella group than in the I/R and partial support (p-Impella) groups. C, NT-proBNP level was significantly higher in the I/R than in sham (thoracotomy only) group, whereas the levels were significantly lower in the t-Impella groups than in the I/R group. Data are expressed as mean±SD. *P<0.05 vs sham; †P<0.05 vs I/R; ‡P<0.001 vs I/R; §P<0.05 vs p-Impella. , the use of Impella during highrisk percutaneous coronary intervention increased cardiac power output, which is the product of cardiac output and mean AP, facilitating successful percutaneous coronary intervention. 20 In the present study, both p-Impella and t-Impella significantly reduced LVEDP, whereas maintaining AP (Table 1) . Our results are consistent with previous reports that Impella was a useful device to avoid hemodynamic instability (including acute heart failure because of increased left atrial pressure and low cardiac output) in the acute setting of MI.
We have reported that LV unloading by LVAD reduces PVA and MVo 2 , and reestablishes oxygen supply-demand balance in the presence of limited supply.
14 Because the mechanical impact on LV is theoretically indistinguishable between Impella and LVAD using a centrifugal pump, we speculated that p-Impella did reduce MVo 2 , whereas t-Impella further reduced MVo 2 . This impact on MVo 2 was translated into the reduction of infarct size.
Effects of LV Mechanical Unloading by Impella on LV Function and Infarct Size at 4 Weeks After I/R
We have reported the effect of LV mechanical unloading by partial and total support of LVAD using a centrifugal pump on infarct size. 14 In that study, LVAD treatment was initiated from the beginning of ischemia to 300 minutes after reperfusion to demonstrate the maximum effect of LV mechanical unloading on MI. However, this protocol of starting mechanical unloading from the onset of acute MI is impractical in clinical settings. To explore clinical applicability of mechanical unloading, we designed the protocol to reflect the realworld clinical management of MI. In the present study, mechanical unloading was started 60 minutes after the onset of ischemia and terminated 60 minutes after reperfusion. We then examined the impact of Impella on LV function and heart failure parameters as well as infarct size at 4 weeks after MI.
Several preclinical investigations have already documented the impact of LVADs, including Impella, on infarct size. Meyns et al 10 reported that Impella reduced the metabolic demands of LV, and the use of Impella in acute MI markedly limited the infarct size assessed 120 minutes after reperfusion in sheep. Smalling et al 11 documented that the use of Hemopump (Johnson and Johnson Interventional Systems Co, Rancho Cordova, CA), a transvalvular axial-flow LV assist device significantly decreased the infarct size by improving collateral blood flow to ischemic tissue and reducing regional work in a canine model of acute MI. Tamareille et al 12 deployed a transvalvular LVAD before reperfusion in a porcine model of acute MI and demonstrated that the infarct size was significantly reduced in LVAD group. They postulated that reduced endothelin-1 release and reduced calcium overload are the potential mechanism by which LV is unloading before reperfusion reduced infarct size.
Clinical trials have also reported the impact of Impella on long-term outcomes. Engström et al 23 reported that recovery of LV ejection fraction was significantly greater in patients who had received 3-day Impella support after ST-segment-elevation MI, after a mean follow-up duration of 2.9±0.6 years in the Impella group and 3.0±0.3 years in the control group. O'Neill et al 24 reported that early initiation of Impella support before percutaneous coronary intervention improved 30-day survival in patients with cardiogenic shock complicating acute MI.
In the present study, both p-Impella and t-Impella reduced infarct size and improved LV function at 4 weeks after MI. Especially, t-Impella significantly improved the parameters of LV contractility such as LV ejection fraction ( Figure 4 ) and LV end-systolic elastance ( Figure 5A and 5B) and decreased NT-proBNP ( Figure 5C ). In addition, t-Impella markedly reduced infarct size by >80% relative to I/R ( Figure 6B ). We assumed that the greater impact of t-Impella on infarct size and LV function compared with p-Impella might result from the difference in MVo 2 reduction between p-Impella and t-Impella in the acute phase of MI. The effect of Impella support during acute MI in reducing infarct size can be extrapolated from previous reports. However, in the present study, we stratified the support level of Impella into partial and total support and demonstrated the impact of the 2 support levels on LV function as well as on infarct size at 4 weeks after MI. The impact of t-Impella on infarct size and LV function greatly exceeded that of p-Impella. Thus, it is fair to say that LV mechanical unloading by the total support of Impella is a therapeutic option to maximize the beneficial effects of Impella in acute MI.
Cardiac remodeling is one of the cardinal manifestations of heart failure. However, our model of I/R did not show eccentric cardiac remodeling. It is conceivable that the timing of evaluation in LV was too early to assess eccentric cardiac remodeling in this model. Furthermore, the fact that our model was not permanent MI, and thus infarct size was rather small, may also attribute to the results. Nevertheless, despite the lack of cardiac remodeling, t-Impella markedly improved hemodynamics and a biomarker of heart failure, NTproBNP. Therefore, it is reasonable to conjecture that t-Impella has a major beneficial impact in protecting heart failure after acute MI.
We focused on the reduction of PVA by Impella in this study. However, previous studies indicated that PVA contributes to approximately one-half of MVo 2 .
14 Thus, even if PVA is reduced to zero (total unloading), PVA lowering alone cannot reduce MVo 2 by >50%. The major determinant of the rest of MVo 2 is heart rate.
Heart rate reduction is also known to reduce MVo 2 independent of PVA. 25 Therefore, it is conceivable that adding bradycardic agent such as a selective If current inhibitor (ivabradine) to Impella may further reduce MVo 2 . It remains to be studied whether further MVo 2 reduction is translated into clinical benefits.
Limitations
There are several limitations in this study. First, we performed I/R experiments under anesthetized condition. Because isoflurane is well known to protect myocardium against ischemia, 26, 27 the quantitative results measured under isoflurane-induced anesthesia may differ from those under conscious condition. However, the period and depth of anesthesia were not different among groups. Thus, comparison of infarct size among 4 groups is valid, and the results may reflect the trend in the conscious state.
Second, as we addressed in the discussion, an Impella pump that can be inserted percutaneously and capable of generating flow >5 L/min in acute MI setting is currently unavailable. 28 In humans, pumping capacity of at least 5 L/min is required to establish total LVAD-dependent circulation. To establish total support by Impella, the development of high-flow percutaneous pumps that can be inserted via standard catheter technique through the femoral artery in acute MI setting is essential.
Last, we initiated Impella support from 60 minutes after ischemia onset to 60 minutes after reperfusion. Because previous reports indicated that earlier LVAD or Impella unloading before reperfusion is more efficient to reduce infarct size, 11, 13, 29 we hypothesized that delaying the timing of Impella support may attenuate its impact on infarct size. In addition, the optimal timing to terminate Impella support remains unknown. In this study, we terminated Impella support 60 minutes after reperfusion because we assumed that the Impella is used only in catheterization rooms. Further investigations are needed to identify the optimal timing and period of Impella support in the treatment of acute MI.
Conclusions
LV mechanical unloading by the total support of Impella only in the acute phase of MI reduced infarct size and prevented subsequent heart failure in a dog model of I/R. Total support by Impella may be a powerful therapeutic option for acute MI.
